Present role of positron emission tomography in the diagnosis and monitoring of peripheral inflammatory arthritis: A systematic review

Arthritis Care and Research

Volumn 66, Issue 1, 2014, Pages 120-130

  Bruijnen, S T G ^a   Gent, Y Y J ^a   Voskuyl, A E ^a   Hoekstra, O S ^a   Van Der Laken, C J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11;

ACUPUNCTURE; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL INFLAMMATORY ARTHRITIS; POSITRON EMISSION TOMOGRAPHY; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYNOVITIS; SYNOVIUM; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SYNOVIAL MEMBRANE; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 84891074509     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22184     Document Type: Article

References (53)

1. Jones T,. The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med 1996; 23: 207-11.
2. Tomasi G, Turkheimer F, Aboagye E,. Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol 2012; 14: 131-46.
3. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM,. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 1975; 16: 210-24.
4. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-79.
5. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME,. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42 Suppl: 1S-93S.
6. Tan AL, Keen HI, Emery P, McGonagle D,. Imaging inflamed synovial joints. Methods Mol Med 2007; 135: 3-26.
7. Larson SM,. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med 1994; 35: 1653-5.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
9. Zasadny KR, Wahl RL,. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy- d -glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-50.
10. Palmer WE, Rosenthal DI, Schoenberg OI, Fischman AJ, Simon LS, Rubin RH, et al. Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy- d -glucose. Radiology 1995; 196: 647-55.
11. 18F-FDG PET. J Nucl Med 2004; 45: 956-64.
12. Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med 2009; 23: 783-91.
13. Tateishi U, Imagawa T, Kanezawa N, Okabe T, Shizukuishi K, Inoue T, et al. PET assessment of disease activity in children with juvenile idiopathic arthritis. Pediatr Radiol 2010; 40: 1781-8.
14. Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, et al. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford) 2012; 51: 1484-91.
15. 18F-FDG-PET as a valuable adjunct to clinical and response assessment in rheumatoid arthritis and seronegative spondyloarthropathies. World J Radiol 2012; 4: 462-8.
16. Goerres GW, Forster A, Uebelhart D, Seifert B, Treyer V, Michel B, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. Clin Nucl Med 2006; 31: 386-90.
17. 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs. Eur J Nucl Med Mol Imaging 2013; 40: 403-10.
18. 18F-FDG PET imaging of rheumatoid knee synovitis correlates with dynamic magnetic resonance and sonographic assessments as well as with the serum level of metalloproteinase-3. Eur J Nucl Med Mol Imaging 2006; 33: 275-80.
19. Elzinga EH, van der Laken CJ, Comans EF, Lammertsma AA, Dijkmans BA, Voskuyl AE,. 2-deoxy-2-[F-18]fluoro- d -glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 2007; 9: 357-60.
20. Taniguchi Y, Arii K, Kumon Y, Fukumoto M, Ohnishi T, Horino T, et al. Positron emission tomography/computed tomography: a clinical tool for evaluation of enthesitis in patients with spondyloarthritides. Rheumatology (Oxford) 2010; 49: 348-54.
21. Okabe T, Shibata H, Shizukuishi K, Yoneyama T, Inoue T, Tateishi U,. F-18 FDG uptake patterns and disease activity of collagen vascular diseases-associated arthritis. Clin Nucl Med 2011; 36: 350-4.
22. 11C- d -deprenyl in patients with rheumatoid arthritis: evaluation of knee joint inflammation before and after intra-articular glucocorticoid treatment. Scand J Rheumatol 1997; 26: 43-8.
23. 18F-fluoro-2-deoxy- d -glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum 2003; 48: 3077-84.
24. 11C-(R)-PK11195 and positron emission tomography. Arthritis Rheum 2008; 58: 3350-5.
25. Polisson RP, Schoenberg OI, Fischman A, Rubin R, Simon LS, Rosenthal D, et al. Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 819-25.
26. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
27. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244-57.
28. 18F-FDG PET with MRI for monitoring response to treatment in rheumatoid arthritis. Eur J Nucl Med Mol Imaging 2010; 37: 1047.
29. Kalicke T, Schmitz A, Risse JH, Arens S, Keller E, Hansis M, et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med 2000; 27: 524-8.
30. Linnman C, Appel L, Fredrikson M, Gordh T, Soderlund A, Langstrom B, et al. Elevated [11C]-D-deprenyl uptake in chronic whiplash associated disorder suggests persistent musculoskeletal inflammation. PLoS One 2011; 6: e19182.
31. Wunder A, Straub RH, Gay S, Funk J, Muller-Ladner U,. Molecular imaging: novel tools in visualizing rheumatoid arthritis. Rheumatology (Oxford) 2005; 44: 1341-9.
32. 11C-(R)-PK11195 PET/CT. J Nucl Med 2011; 52: 33-9.
33. Baillet A, Gaujoux-Viala C, Mouterde G, Pham T, Tebib J, Saraux A, et al. Comparison of the efficacy of sonography, magnetic resonance imaging and conventional radiography for the detection of bone erosions in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2011; 50: 1137-47.
34. Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Ostergaard M,. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum 2003; 48: 955-62.
35. Ostergaard M, Lorenzen I, Henriksen O,. Dynamic gadolinium-enhanced MR imaging in active and inactive immunoinflammatory gonarthritis. Acta Radiol 1994; 35: 275-81.
36. Gent YY, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS, Dijkmans BA, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum 2012; 64: 62-6.
37. 18F-FDG-PET. Ann Nucl Med 2009; 23: 311-6.
38. 18F-FDG PET as a tool to predict the clinical outcome of infliximab treatment of rheumatoid arthritis: an explorative study. J Nucl Med 2011; 52: 77-80.
39. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477-84.
40. Duet M, Pouchot J, Liote F, Faraggi M,. Role for positron emission tomography in skeletal diseases. Joint Bone Spine 2007; 74: 14-23.
41. 18F-FDG-labeled leukocyte PET/CT: initial experience in 21 patients. J Nucl Med 2006; 47: 625-32.
42. 18F- fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev 2008; 21: 209-24.
43. Sugawara Y, Braun DK, Kison PV, Russo JE, Zasadny KR, Wahl RL,. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur J Nucl Med 1998; 25: 1238-43.
44. Zhuang H, Yu JQ, Alavi A,. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005; 43: 121-34.
45. Dorward DA, Lucas CD, Rossi AG, Haslett C, Dhaliwal K,. Imaging inflammation: molecular strategies to visualize key components of the inflammatory cascade, from initiation to resolution. Pharmacol Ther 2012; 135: 182-99.
46. Gu JT, Nguyen L, Chaudhari AJ, Mackenzie JD,. Molecular characterization of rheumatoid arthritis with magnetic resonance imaging. Top Magn Reson Imaging 2011; 22: 61-9.
47. Rosenstein M,. Diagnostic reference levels for medical exposure of patients: ICRP guidance and related ICRU quantities. Health Phys 2008; 95: 528-34.
48. Picano E,. Sustainability of medical imaging. BMJ 2004; 328: 578-80.
49. UNSCEAR 2010 report. 2011. URL: http://www.unscear.org/docs/reports/2010/ UNSCEAR-2010-Report-M.pdf.
50. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging. Version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
51. Wahl RL, Jacene H, Kasamon Y, Lodge MA,. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50 Suppl 1: 122S-50S.
52. 18F-FDG PET-MRI of the hand in rheumatoid arthritis: initial results. Clin Rheumatol 2011; 30: 1247-50.
53. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.